knee osteoarthritis
Conditions
Interventions
Experimental group :moxibustion
control group:Take celecoxib capsules orally
Sponsors
Huaibei People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Meet the diagnostic criteria for knee osteoarthritis set by the China Association of Chinese Medicine; (2) Age: 40 to 75 years old; (3) Stop taking painkillers and hormone drugs during the trial period. (4) No moxibustion treatment has been received in the past month; (5) Be willing to sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those who belong to the late or advanced clinical stage of knee osteoarthritis as stipulated in the "Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Knee Osteoarthritis (2023 Edition)" issued by the China Association of Chinese Medicine, or have a Recht grade of III-IV on MRI examination, with severe joint deformity and destruction of articular cartilage; (2) Patients with concurrent other bone diseases such as knee joint tuberculosis, tumors, rheumatism and rheumatoid arthritis, etc., which do not belong to osteoarthritis; (3) Patients who have received intravascular injection of glucocorticoids or viscoelastic substance supplementation therapy (such as sodium hyaluronate, etc.) for knee osteoarthritis in the past six months, or those who have undergone knee replacement surgery; (4) Combined with severe cardiovascular and cerebrovascular, liver, kidney, respiratory, metabolic system diseases and severe mental illness; (5) Participate in other knee osteoarthritis experimental studies simultaneously; (6) Those with contraindications to magnetic resonance imaging (MRI) scans, such as having non-removable metal substances implanted in the body, claude-phobia syndrome, etc. (7) Allergic to moxibustion smoke; (8) Pregnant or lactating women; (9) Unwilling to be randomly grouped.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic effect evaluation index;Overall therapeutic effect evaluation of the patient;Molecular biology indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic indicators and baseline indicators; | — |
Countries
China
Contacts
Public ContactLei liu
Huaibei People's Hospital
Outcome results
None listed